1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bachem Holding AG Class B

Bachem Holding AG Class B

81.15
CHF
-1.10
(-1.34%)
5.67BMarket Cap
Mar 04Next Earn
Bachem Holding AG Class B
LSE:0QND
(London Stock Exchange)

Recent

price

81.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
2.27
2.16
2.33
2.53
2.72
3.08
3.49
3.85
4.16
4.53
5.74
7.1
7.21
7.73
8.07
9.27
- -
Revenue per Share
0.42
0.14
0.23
0.35
0.43
0.47
0.61
0.62
0.69
0.78
1.12
1.62
1.37
1.5
1.6
1.98
- -
Basic EPS, GAAP
0.29
0.17
0.4
0.55
0.47
0.53
-0.16
-0.22
-0.18
0.49
0.66
-0.27
-0.67
-0.25
-1.84
-0.77
- -
Free Cash Flow per Basic Share
0.3
0.25
0.15
0.3
0.35
0.25
0.3
0.35
0.4
0.4
0.6
0.29
0.7
0.75
0.8
0.41
- -
Dividend per Share
10.77
4.95
4.94
4.98
5.16
5.22
5.39
5.51
5.66
6.4
6.8
15.2
15.87
17.61
18.55
19.46
19.27
Book Value per Share
10.22
4.65
4.8
4.84
5.04
5.08
5.25
5.32
5.46
6.21
6.61
15.02
15.68
17.43
18.27
19.09
18.86
Tangible Book Value per Share
67
67
67
68
68
68
68
68
68
69
70
71
74
75
75
75
75
Basic Weighted Avg Shares
153
146
157
171
184
209
236
262
283
314
402
503
532
577
605
695
- -
Sales/Revenue/Turnover
10.25
10.19
14.2
17.25
18
18.45
19.05
18.68
19.4
19.88
24.05
25.62
23.93
22.41
21.98
24.07
- -
Operating Margin (%)
18
18
22
18
19
18
20
21
23
25
26
28
33
37
43
47
- -
Depreciation Expense
28
9
16
24
29
32
41
42
47
54
78
115
101
112
120
149
- -
Net Income, GAAP
11.53
23.12
20.87
18.32
20.03
14.59
10.2
13.64
14.63
10.28
14.18
12.71
10.16
9.94
11.07
4.86
- -
Effective Tax Rate (%)
18.51
6.45
9.89
13.83
15.8
15.26
17.42
15.97
16.51
17.27
19.42
22.79
18.93
19.38
19.87
21.41
- -
Profit Margin (%)
147
129
138
148
161
148
126
115
111
227
215
699
596
677
542
321
312
Working Capital
- -
1
- -
- -
- -
- -
- -
- -
- -
60
- -
- -
- -
- -
- -
- -
- -
LT Debt
359
334
334
336
349
353
365
374
384
448
476
1,121
1,170
1,321
1,391
1,458
1,444
Total Equity
3.75
3.05
4.55
6.19
7.5
8.69
9.98
9.68
9.28
10.23
16.01
13.86
9.84
9.27
8.65
11.08
- -
Return on Invested Capital (%)
8.02
2.67
4.17
6.26
7.79
8.62
10.46
9.45
9.37
10.01
15.21
14.22
8.71
8.98
8.87
10.47
- -
Return on Capital (%)
7.7
2.72
4.66
7.05
8.48
9.06
11.47
11.3
12.3
13.02
16.91
14.36
8.79
8.98
8.87
10.44
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
75
Market Capitalization
4,348
4,489
5,669

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
711
727
829
Cash, Cash Equivalents & STI
29
31
52
Accounts Receivable, Net
174
179
174
Inventories
483
494
577
Total Current Liabilities
292
405
517
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.43%
32.61%
4.83%
Free Cash Flow
9.05%
108.21%
-58.19%
Net Income, GAAP
17.97%
15.41%
23.74%
Sales/Revenue/Turnover
13.03%
11.82%
14.84%
Total Cash Common Dividend
17.22%
13.51%
-48.77%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
605
2025
- -
- -
695
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.6
2025
- -
- -
1.98
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.8
2025
- -
- -
0.41
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bachem Holding AG Bachem Holding AG is a leading innovation-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacture of peptides and oligonucleotides for pharmaceutical and biotechnology companies worldwide. Founded in 1971 and headquartered in Bubendorf, Switzerland, the company provides a comprehensive portfolio of products and services, including catalog peptides, amino acid derivatives and biochemicals for research purposes; custom peptide synthesis and oligonucleotides for clinical development; generic active pharmaceutical ingredients (APIs) and commercial-scale GMP manufacturing of new chemical entities (NCEs); as well as services such as CMC development, project management and process optimization under the Bachem and Clinalfa brands. Bachem operates internationally through manufacturing sites in Bubendorf and Vionnaz (Switzerland), Torrance and Vista (USA), St. Helens (UK), and sales offices in Europe, North America and Asia, serving research, diagnostic, cosmetic and therapeutic markets across these regions. Recent developments include securing a CHF 1 billion peptide supply contract spanning 2025-2029 with a major client, enabling capacity expansions at existing sites including a large-scale facility in Bubendorf and high-volume production in Vista; planning a new manufacturing site in Eiken, Switzerland, with construction applications in 2025; reporting strong first-half 2025 sales growth prompting an upward revision of full-year guidance to 13-18% in local currencies; and ongoing investments in its global network to support oligonucleotide and peptide production amid rising demand.

Company News

Company News APIChatGPT